Question-and-Answer SessionGood to see you. Let's just kick it off with a bit of a kind of discussion of the MASH space, all the commercial developments. We've had some regulatory developments with respect to noninvasive diagnosis. Give us kind of the state of the market in your view, and then we can get into pegozafermin.Rohan PalekarCEO & Director Sure. So I think, Geoff, it's a great time to be in the MASH space. I think this was a long time coming, right, where this is a disease state or an indication w ...